Legal & General Group’s Fortress Biotech FBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-387
Closed -$5K 3466
2022
Q2
$5K Sell
387
-144
-27% -$2.13K ﹤0.01% 3442
2022
Q1
$11K Buy
531
+31
+6% +$849 ﹤0.01% 3382
2021
Q4
$19K Hold
500
﹤0.01% 3286
2021
Q3
$24K Hold
500
﹤0.01% 3210
2021
Q2
$27K Buy
500
+45
+10% +$2.71K ﹤0.01% 3174
2021
Q1
$24K Sell
455
-2,516
-85% -$142K ﹤0.01% 3052
2020
Q4
$141K Buy
2,971
+2,484
+510% +$108K ﹤0.01% 2492
2020
Q3
$30K Sell
487
-149
-23% -$7.59K ﹤0.01% 2849
2020
Q2
$26K Buy
+636
New +$23.6K ﹤0.01% 2950
2019
Q3
Sell
-333
Closed -$7K 3374
2019
Q2
$7K Hold
333
﹤0.01% 3415
2019
Q1
$9K Hold
333
﹤0.01% 3261
2018
Q4
$4K Hold
333
﹤0.01% 3351
2018
Q3
$8K Hold
333
﹤0.01% 3343
2018
Q2
$15K Hold
333
﹤0.01% 3248
2018
Q1
$23K Hold
333
﹤0.01% 3075
2017
Q4
$20K Sell
333
-165
-33% -$9.72K ﹤0.01% 3143
2017
Q3
$33K Buy
498
+217
+77% +$14.6K ﹤0.01% 3039
2017
Q2
$20K Hold
281
﹤0.01% 3188
2017
Q1
$16K Buy
281
+64
+29% +$2.86K ﹤0.01% 3127
2016
Q4
$9K Buy
+217
New +$8.11K ﹤0.01% 3222

Other funds holding FBIO

Legal & General Group's FBIO Position: Q3 2022 in Review

Legal & General Group sold out of Fortress Biotech (FBIO) in Q3 2022, closing a stake of 387 shares — an estimated $5K sold.

Legal & General Group first reported a position in FBIO in Q4 2016 and held it in 20 quarters. The position peaked at $141K in Q4 2020. 64 funds tracked by Wall St. Rank hold FBIO as of Q3 2022.

  • Legal & General Group reported no remaining Fortress Biotech position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 387 Fortress Biotech shares in Q3 2022, an estimated $5K.
  • Legal & General Group first reported a position in Fortress Biotech in Q4 2016 and held it in 20 quarters.
  • Legal & General Group's Fortress Biotech position peaked at $141K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.